You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarbamazepine
Accession NumberDB00564  (APRD00337)
TypeSmall Molecule
GroupsApproved, Investigational
Description

An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. [PubChem]

Structure
Thumb
Synonyms
5-Carbamoyl-5H-dibenz(b,f)azepine
5-Carbamoyl-5H-dibenz[b,F]azepine
5-Carbamoyl-5H-dibenzo(b,F)azepine
5-Carbamyl-5H-dibenzo(b,F)azepine
5H-Dibenz(b,F)azepine-5-carboxamide
Carbamazepen
Carbamazepin
Carbamazepina
Carbamazépine
Carbamazepinum
CBZ
External Identifiers
  • G 32 883
  • SPD417
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bio-carbamazepinetablet200 mgoralBiomed Pharma2003-08-202010-03-16Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carbamazepinetablet, extended release200 mg/1oralKAISER FOUNDATION HOSPITALS2009-10-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mg/1oralPrasco Laboratories2011-12-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mg/1oralPrasco Laboratories2011-12-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mg/1oralPrasco Laboratories2011-12-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine 200 Tab 200mgtablet200 mgoralPro Doc Limitee1982-12-312013-07-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carbamazepine 200mg Tabletstablet200 mgoralLaboratoires Confab IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carbamazepine CRtablet (extended-release)200 mgoralPro Doc Limitee2013-11-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carbamazepine CRtablet (extended-release)400 mgoralPro Doc Limitee2013-11-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carbamazepine ERtablet, extended release200 mg/1oralSandoz Inc1996-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release400 mg/1oralAmerican Health Packaging2013-06-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release100 mg/1oralSandoz Inc1996-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release200 mg/1oralAmerican Health Packaging2013-06-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release400 mg/1oralPhysicians Total Care, Inc.2009-10-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release400 mg/1oralSandoz Inc1996-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine-CR -(200mg)tablet (extended-release)200 mgoralPro Doc Limitee2001-05-222009-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carbamazepine-CR -(400mg)tablet (extended-release)400 mgoralPro Doc Limitee2001-05-222009-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carbamazepineer ERtablet, extended release400 mg/1oralREMEDYREPACK INC.2016-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbatrolcapsule, extended release300 mg/1oralShire US Manufacturing Inc.1997-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbatrolcapsule, extended release200 mg/1oralShire US Manufacturing Inc.1997-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbatrolcapsule, extended release100 mg/1oralShire US Manufacturing Inc.1999-12-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbatrolcapsule, extended release300 mg/1oralPhysicians Total Care, Inc.2009-10-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dom-carbamazepinetablet200 mgoralDominion PharmacalNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-carbamazepine CRtablet (extended-release)200 mgoralDominion Pharmacal1998-09-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-carbamazepine CRtablet (extended-release)400 mgoralDominion Pharmacal1998-09-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Equetrocapsule, extended release300 mg/1oralValidus Pharmaceuticals LLC2004-12-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Equetrocapsule, extended release200 mg/1oralValidus Pharmaceuticals LLC2004-12-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Equetrocapsule, extended release100 mg/1oralValidus Pharmaceuticals LLC2004-12-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mazepinetablet200 mgoralBiomed Pharma1981-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-carbamazepine CRtablet (extended-release)400 mgoralMylan Pharmaceuticals Ulc2000-03-16Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-carbamazepine CRtablet (extended-release)200 mgoralMylan Pharmaceuticals Ulc2000-03-16Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-carbamazepine Tab 200mgtablet200 mgoralNu Pharm Inc1993-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-carbamazepine CRtablet (extended-release)400 mgoralPharmel Inc1998-09-032009-10-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-carbamazepine CRtablet (extended-release)200 mgoralPharmel Inc1998-09-032009-10-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-carbamazepinetablet200 mgoralPharmascience Inc1986-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-carbamazepinetablet (chewable)100 mgoralPharmascience Inc2002-08-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-carbamazepinetablet200 mgoralPharmascience IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-carbamazepinetablet (chewable)200 mgoralPharmascience Inc2002-08-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-carbamazepine CRtablet (extended-release)200 mgoralPharmascience IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-carbamazepine CRtablet (extended-release)400 mgoralPharmascience IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-carbamazepine-CRtablet (extended-release)400 mgoralPharmascience Inc1998-05-28Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-carbamazepine-CRtablet (extended-release)200 mgoralPharmascience Inc1998-05-28Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz-carbamazepine Chewtabstablet200 mgoralSandoz Canada Incorporated2006-02-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz-carbamazepine Chewtabstablet100 mgoralSandoz Canada Incorporated2006-02-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz-carbamazepine CRtablet (extended-release)400 mgoralSandoz Canada Incorporated2006-02-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz-carbamazepine CRtablet (extended-release)200 mgoralSandoz Canada Incorporated2006-02-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Taro-carbamazepinetablet200 mgoralTaro Pharmaceuticals Inc2014-05-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Taro-carbamazepinesuspension100 mgoralTaro Pharmaceuticals Inc2011-10-07Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Taro-carbamazepine Chewable Tablets 100mgtablet (chewable)100 mgoralTaro Pharmaceuticals Inc2002-04-19Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Taro-carbamazepine Chewable Tablets 200mgtablet (chewable)200 mgoralTaro Pharmaceuticals Inc2002-04-19Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Taro-carbamazepine CR 200 mgtablet (extended-release)200 mgoralTaro Pharmaceuticals Inc1998-05-27Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Taro-carbamazepine CR 400 mgtablet (extended-release)400 mgoralTaro Pharmaceuticals Inc1998-05-27Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Taro-carbamazepine Tab 200mgtablet200 mgoralTaro Pharmaceuticals Inc1994-12-312001-08-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tegretolsuspension100 mg/5mLoralNovartis Pharmaceuticals Corporation1987-12-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretoltablet200 mg/1oralREMEDYREPACK INC.2015-10-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretoltablet200 mg/1oralNovartis Pharmaceuticals Corporation1968-03-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretol - Sus 100mg/5mlsuspension100 mgoralNovartis Pharmaceuticals Canada Inc1996-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tegretol 200mgtablet200 mgoralNovartis Pharmaceuticals Canada Inc1969-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tegretol Chewtabs 100mgtablet100 mgoralNovartis Pharmaceuticals Canada Inc1985-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tegretol Chewtabs 200mgtablet200 mgoralNovartis Pharmaceuticals Canada Inc1985-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tegretol CR Tab 200mgtablet (extended-release)200 mgoralNovartis Pharmaceuticals Canada Inc1988-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tegretol CR Tab 400mgtablet (extended-release)400 mgoralNovartis Pharmaceuticals Canada Inc1988-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tegretol XRtablet, extended release400 mg/1oralNovartis Pharmaceuticals Corporation1996-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretol XRtablet, extended release200 mg/1oralNovartis Pharmaceuticals Corporation1996-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretol XRtablet, extended release100 mg/1oralNovartis Pharmaceuticals Corporation1996-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretolxr XRtablet, extended release100 mg/1oralREMEDYREPACK INC.2015-10-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Teva-carbamazepinetablet200 mgoralTeva Canada Limited1988-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Carbamazepine Tab 200mgtablet200 mgoralApotex Inc1980-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-carbamazepine CRtablet (extended-release)400 mgoralApotex IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-carbamazepine CRtablet (extended-release)200 mgoralApotex IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carbamazepinetablet, extended release200 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mg/1oralREMEDYREPACK INC.2015-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mg/1oralNostrum Laboratories, Inc.2011-05-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralCardinal Health2000-10-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralPreferred Pharmaceuticals, Inc.2014-04-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralREMEDYREPACK INC.2011-05-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1990-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet100 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-10-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralSTAT Rx USA LLC2009-12-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mg/1oralApotex Corp.2012-03-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralCardinal Health2010-09-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinesuspension100 mg/5mLoralPrecision Dose Inc.2007-02-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable200 mg/1oralREMEDYREPACK INC.2013-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralActavis Elizabeth LLC1995-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralTaro Pharmaceuticals U.S.A., Inc.1996-10-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralTorrent Pharmaceuticals Limited2009-08-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mg/1oralApotex Corp.2012-03-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralPhysicians Total Care, Inc.1995-07-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralREMEDYREPACK INC.2010-12-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mg/1oralTeva Pharmaceuticals USA Inc2013-02-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinesuspension100 mg/5mLoralGolden State Medical Supply, Inc.2004-09-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinesuspension200 mg/10mLoralPrecision Dose Inc.2003-09-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralNorthwind Pharmaceuticals, LLC2015-03-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralTorrent Pharmaceuticals Limited2009-10-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralApotex Corp.2002-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralPhysicians Total Care, Inc.1993-09-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralREMEDYREPACK INC.2011-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mg/1oralTeva Pharmaceuticals USA Inc2013-02-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralGolden State Medical Supply, Inc.2014-03-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralAmerican Health Packaging2014-04-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralMylan Institutional Inc.1996-05-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralMajor Pharmaceuticals2010-09-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinesuspension100 mg/5mLoralMorton Grove Pharmaceuticals, Inc.2002-06-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralA S Medication Solutions Llc1996-10-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralPd Rx Pharmaceuticals, Inc.1996-10-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mg/1oralTeva Pharmaceuticals USA Inc2013-07-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralClinical Solutions Wholesale2009-08-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralContract Pharmacy Services Pa2010-02-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralMylan Institutional Inc.1995-09-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralMajor Pharmaceuticals2010-03-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralGolden State Medical Supply, Inc.2000-10-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, extended release400 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralMc Kesson Contract Packaging2011-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralAidarex Pharmaceuticals LLC1996-10-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralTeva Pharmaceuticals USA Inc1995-09-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralClinical Solutions Wholesale2009-10-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralTYA Pharmaceuticals1996-10-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralMc Kesson Contract Packaging2011-10-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralUnit Dose Services1996-10-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralUpsher Smith Laboratories, Inc1996-10-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralGolden State Medical Supply, Inc.1996-10-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, extended release100 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mg/1oralNostrum Laboratories, Inc.2011-05-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralREMEDYREPACK INC.2014-11-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralCardinal Health1996-10-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, extended release400 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralbryant ranch prepack2011-05-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mg/1oralNostrum Laboratories, Inc.2011-05-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralCardinal Health2011-10-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable200 mg/1oralPreferred Pharmaceuticals, Inc2012-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mg/1oralREMEDYREPACK INC.2011-07-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2005-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinesuspension100 mg/5mLoralTaro Pharmaceuticals U.S.A., Inc.2004-09-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mg/1oralApotex Corp.2012-03-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, extended release200 mg/1oralCardinal Health2009-03-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Epitoltablet200 mg/1oralTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
ActebralSanofi-Aventis
AnlepticSquare
BistonZentiva
CarbamatAstraZeneca
NeurotopGerot
TEGretol ChewtabsNot Available
TEGretol-CRNovartis
TEGretol-XRNovartis
TerilTaro
TimonilDesitin
VersitolMicro Synapse
VersizurMicro Labs
Brand mixturesNot Available
SaltsNot Available
Categories
UNII33CM23913M
CAS number298-46-4
WeightAverage: 236.2686
Monoisotopic: 236.094963016
Chemical FormulaC15H12N2O
InChI KeyInChIKey=FFGPTBGBLSHEPO-UHFFFAOYSA-N
InChI
InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
IUPAC Name
2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide
SMILES
NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Azepine
  • Benzenoid
  • Urea
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of epilepsy and pain associated with true trigeminal neuralgia.
PharmacodynamicsCarbamazepine, an anticonvulsant structurally similar to tricyclic antidepressants, is used to treat partial seizures, tonic-clonic seizures, pain of neurologic origin such as trigeminal neuralgia, and psychiatric disorders including manic-depressive illness and aggression due to dementia. The response to carbamazepine is variable and may be due to its variable transport, especially across the blood-brain-barrier. The transporter that may confer drug resistance is RALBP1.
Mechanism of actionCarbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with reduction of post-tetanic potentiation of synaptic transmission in the spinal cord. Carbamazepine also possesses anticholinergic, central antidiuretic, antiarrhythmic, muscle relaxant, antidepressant (possibly through blockade of norepinephrine release), sedative, and neuromuscular-blocking properties.
AbsorptionIn clinical studies, carbamazepine suspension, conventional tablets, and extended-release tablets delivered equivalent amounts of drug to the systemic circulation. However, it has been observed that the suspension is somewhat faster absorbed. Furthermore, the extended-release tablet is slightly slower than the conventional tablet. The bioavailability of the extended-release tablet is 89%, compared to the suspension. Plasma levels of carbamazepine are variable. The time to peak concentration for the different formulations are as follows: Suspension = 1.5 hours; Conventional tablets = 4-5 hours; Extended-release tablets = 3-12 hours.
Volume of distributionNot Available
Protein binding76% bound to plasma proteins.
Metabolism

Hepatic. CYP3A4 is the primary isoform responsible for the formation of carbamazepine-10,11-epoxide. This metabolite is active and shown to be equipotent to carbamazepine as an anticonvulsant. Carbamazepine is more rapidly metabolized to the aforementioned metabolite in younger patients than in adults. It also undergoes glucuronidation via UGT2B7, however this finding has been disputed.

SubstrateEnzymesProduct
Carbamazepine
10,11-EpoxycarbamazepineDetails
Carbamazepine
3-hydroxycarbamazepineDetails
Carbamazepine
Not Available
Carbamazepine 2,3-epoxideDetails
3-hydroxycarbamazepine
2,3-DihydroxycarbamazepineDetails
Carbamazepine 2,3-epoxide
Not Available
2-hydroxycarbamazepineDetails
2-hydroxycarbamazepine
2-hydroxyiminostilbeneDetails
2-hydroxyiminostilbene
Not Available
Carbamazepine iminoquinoneDetails
2-hydroxycarbamazepine
Not Available
2,3-DihydroxycarbamazepineDetails
2,3-Dihydroxycarbamazepine
Not Available
Carbamazepine-O-quinoneDetails
10,11-Epoxycarbamazepine
10,11-DihydroxycarbamazepineDetails
Carbamazepine 2,3-epoxide
Not Available
3-hydroxycarbamazepineDetails
Route of elimination72% of the dose is in the urine while 28% is in the feces. Hydroxylated and conjugated metabolites are largely what was recovered in the urine. 3% of the dose is recovered as unchanged carbamazepine.
Half lifeInitial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.
ClearanceNot Available
ToxicityMild ingestions cause vomiting, drowsiness, ataxia, slurred speech, nystagmus, dystonic reactions, and hallucinations. Severe intoxications may produce coma, seizures, respiratory depression, and hypotension
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Sodium channel protein type 1 subunit alpha
Gene symbol: SCN1A
UniProt: P35498
rs3812718 Not AvailableIVS5N + 5 G>ACarbamazepine resistant therapy, higher maintenance dose24052718
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Heat shock 70 kDa protein 1-like
Gene symbol: HSPA1L
UniProt: P34931
rs2227956 Not AvailableT alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
Heat shock 70 kDa protein 1A/1B
Gene symbol: HSPA1A
UniProt: P08107
rs506770 Not AvailableC alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
Heat shock 70 kDa protein 1A/1B
Gene symbol: HSPA1A
UniProt: P08107
rs1043620 Not AvailableC alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
HLA class I histocompatibility antigen, B-15 alpha chain
Gene symbol: HLA-B
UniProt: P30464
rs3130690 Not AvailableT alleleStevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538176
HLA class I histocompatibility antigen, A-31 alpha chain
Gene symbol: HLA-A
UniProt: P16189
rs1264511 Not AvailableG alleleMacropapular eruption16538176
Promotilin
Gene symbol: MLN
UniProt: P12872
rs2894342 Not AvailableA alleleHypersensitivity syndrome16538176
Flotillin-1
Gene symbol: FLOT1
UniProt: O75955
rs3909184 HLA-B*1502G > CPatients with the CG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the CC genotype (non-carriers of HLA-b*1502)18637831
Mucin-21
Gene symbol: MUC21
UniProt: Q5SSG8
rs2844682 HLA-B*1502G>APatients with the AG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the AA genotype18637831
Flotillin-1
Gene symbol: FLOT1
UniProt: O75955
rs3909184 HLA-B*1502G > CPatients with the CG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the CC genotype (non-carriers of HLA-b*1502)15057820
Mucin-21
Gene symbol: MUC21
UniProt: Q5SSG8
rs2844682 HLA-B*1502G>APatients with the AG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the AA genotype15057820
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9962
Blood Brain Barrier+0.9958
Caco-2 permeable+0.6538
P-glycoprotein substrateNon-substrate0.6466
P-glycoprotein inhibitor INon-inhibitor0.8748
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7466
CYP450 2D6 substrateSubstrate0.884
CYP450 3A4 substrateNon-substrate0.6204
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8222
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7358
Ames testNon AMES toxic0.5554
CarcinogenicityNon-carcinogens0.8848
BiodegradationNot ready biodegradable0.978
Rat acute toxicity2.1131 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9653
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
  • Validus pharmaceuticals inc
  • Taro pharmaceutical industries ltd
  • Wockhardt eu operations (swiss) ag
  • Novartis pharmaceuticals corp
  • Taro pharmaceuticals usa inc
  • Cadista pharmaceuticals inc
  • Torrent pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Inwood laboratories inc sub forest laboratories inc
  • Pliva inc
  • Usl pharma inc
  • Warner chilcott div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Tabletoral200 mg
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral200 mg/1
Capsule, extended releaseoral300 mg/1
Suspensionoral200 mg/10mL
Tabletoral100 mg/1
Tablet, chewableoral100 mg/1
Tablet, chewableoral200 mg/1
Tablet (chewable)oral100 mg
Tablet (chewable)oral200 mg
Tablet (extended-release)oral200 mg
Tablet (extended-release)oral400 mg
Suspensionoral100 mg/5mL
Tabletoral200 mg/1
Suspensionoral100 mg
Tabletoral100 mg
Tablet, extended releaseoral100 mg/1
Tablet, extended releaseoral200 mg/1
Tablet, extended releaseoral400 mg/1
Prices
Unit descriptionCostUnit
Equetro 300 mg capsule2.65USD capsule
TEGretol XR 400 mg 12 Hour tablet2.42USD tablet
Carbamazepine powder2.26USD g
Tegretol xr 400 mg tablet2.19USD tablet
Carbatrol 100 mg 12 Hour Capsule2.18USD capsule
Equetro 200 mg capsule2.15USD capsule
CarBAMazepine 400 mg 12 Hour tablet2.05USD tablet
Carbatrol 300 mg 12 Hour Capsule1.95USD capsule
Carbatrol 200 mg 12 Hour Capsule1.92USD capsule
Carbatrol er 100 mg capsule1.84USD capsule
Carbatrol er 200 mg capsule1.84USD capsule
Carbatrol er 300 mg capsule1.84USD capsule
Equetro 100 mg capsule1.74USD capsule
TEGretol XR 200 mg 12 Hour tablet1.45USD tablet
Tegretol xr 200 mg tablet1.1USD tablet
CarBAMazepine 200 mg 12 Hour tablet1.03USD tablet
TEGretol XR 100 mg 12 Hour tablet0.97USD tablet
Tegretol Cr 400 mg Sustained-Release Tablet0.84USD tablet
Tegretol 200 mg tablet0.75USD tablet
Tegretol xr 100 mg tablet0.55USD tablet
Tegretol Cr 200 mg Sustained-Release Tablet0.42USD tablet
Mylan-Carbamazepine Cr 400 mg Sustained-Release Tablet0.4USD tablet
Pms-Carbamazepine-Cr 400 mg Sustained-Release Tablet0.4USD tablet
Sandoz Carbamazepine Cr 400 mg Sustained-Release Tablet0.4USD tablet
Tegretol 200 mg Chewable Tablet0.34USD tablet
Carbamazepine 200 mg tablet0.31USD tablet
Epitol 200 mg tablet0.3USD tablet
CarBAMazepine 100 mg Chew Tabs0.25USD tab
Mylan-Carbamazepine Cr 200 mg Sustained-Release Tablet0.2USD tablet
Pms-Carbamazepine-Cr 200 mg Sustained-Release Tablet0.2USD tablet
Sandoz Carbamazepine Cr 200 mg Sustained-Release Tablet0.2USD tablet
Tegretol 100 mg Chewable Tablet0.17USD tablet
CarBAMazepine 100 mg/5ml Suspension0.16USD ml
Pms-Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Sandoz Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Taro-Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Apo-Carbamazepine 200 mg Tablet0.08USD tablet
Novo-Carbamaz 200 mg Tablet0.08USD tablet
Nu-Carbamazepine 200 mg Tablet0.08USD tablet
Pms-Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Sandoz Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Taro-Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Tegretol 20 mg/ml Suspension0.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States52846621994-02-082011-02-08
United States69772532004-05-192024-05-19
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point204-206Schindier, W.; U.S. Patent 2,948,718; August 9, 1960; assigned to Geigy Chemical Corporation.
water solubility17.7 mg/LNot Available
logP2.45DAL POZZO,A ET AL. (1989)
Predicted Properties
PropertyValueSource
Water Solubility0.152 mg/mLALOGPS
logP2.1ALOGPS
logP2.77ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)15.96ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.33 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity71.89 m3·mol-1ChemAxon
Polarizability25 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.72 KB)
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-5z40000000-4b2dc85e8da73b101ed2View in MoNA
1D NMR1H NMR SpectrumNot Available
References
Synthesis Reference

Ketan Dhansukhlal Vyas, Wajid Sajjad Jafri, Ashok Krishna Kulkarni, “Process for preparing carbamazepine from iminostilbene.” U.S. Patent US6245908, issued February, 1998.

US6245908
General References
  1. Staines AG, Coughtrie MW, Burchell B: N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther. 2004 Dec;311(3):1131-7. Epub 2004 Aug 3. Pubmed
  2. Sisodiya SM, Goldstein DB: Drug resistance in epilepsy: more twists in the tale. Epilepsia. 2007 Dec;48(12):2369-70. Pubmed
External Links
ATC CodesN03AF01
AHFS Codes
  • 28:12.92
PDB EntriesNot Available
FDA labelDownload (55.9 KB)
MSDSDownload (71.6 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Carbamazepine.
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Carbamazepine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Carbamazepine.
AcetazolamideThe serum concentration of Carbamazepine can be increased when it is combined with Acetazolamide.
AdenosineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Adenosine.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Carbamazepine.
AlbendazoleThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Carbamazepine resulting in a loss in efficacy.
AllopurinolThe serum concentration of Carbamazepine can be increased when it is combined with Allopurinol.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Carbamazepine.
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Carbamazepine.
AmlodipineThe metabolism of Amlodipine can be increased when combined with Carbamazepine.
AmoxapineThe metabolism of Amoxapine can be increased when combined with Carbamazepine.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Carbamazepine.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Carbamazepine.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Carbamazepine.
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Carbamazepine resulting in a loss in efficacy.
AsenapineThe metabolism of Asenapine can be increased when combined with Carbamazepine.
AtazanavirThe metabolism of Atazanavir can be increased when combined with Carbamazepine.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Carbamazepine.
AzelastineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Carbamazepine.
BatimastatThe metabolism of Batimastat can be increased when combined with Carbamazepine.
BazedoxifeneThe serum concentration of Bazedoxifene can be decreased when it is combined with Carbamazepine.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Carbamazepine.
BendamustineThe serum concentration of Bendamustine can be decreased when it is combined with Carbamazepine.
BepridilThe serum concentration of Carbamazepine can be increased when it is combined with Bepridil.
BetaxololThe metabolism of Betaxolol can be increased when combined with Carbamazepine.
BexaroteneThe serum concentration of Carbamazepine can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Carbamazepine.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Carbamazepine.
BosentanThe serum concentration of Carbamazepine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Carbamazepine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Carbamazepine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Carbamazepine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
BuprenorphineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Carbamazepine.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Carbamazepine.
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Carbamazepine.
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Carbamazepine.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Carbamazepine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbamazepine.
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Carbamazepine.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carbamazepine.
CimetidineThe serum concentration of Carbamazepine can be increased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Carbamazepine can be increased when it is combined with Ciprofloxacin.
CitalopramThe metabolism of Carbamazepine can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Carbamazepine.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Carbamazepine.
ClozapineCarbamazepine may increase the myelosuppressive activities of Clozapine.
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Carbamazepine.
ConivaptanThe serum concentration of Carbamazepine can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Carbamazepine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Carbamazepine.
DabrafenibThe serum concentration of Carbamazepine can be decreased when it is combined with Dabrafenib.
DacarbazineThe metabolism of Dacarbazine can be increased when combined with Carbamazepine.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Carbamazepine.
DanazolThe metabolism of Carbamazepine can be decreased when combined with Danazol.
DarunavirThe serum concentration of Carbamazepine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Carbamazepine.
DeferasiroxThe serum concentration of Carbamazepine can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Carbamazepine.
DesipramineThe metabolism of Desipramine can be increased when combined with Carbamazepine.
DesmopressinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Carbamazepine.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Carbamazepine.
DiclofenamideThe serum concentration of Carbamazepine can be increased when it is combined with Diclofenamide.
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Carbamazepine.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Carbamazepine.
DiltiazemThe serum concentration of Carbamazepine can be increased when it is combined with Diltiazem.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Carbamazepine.
DoxepinThe metabolism of Doxepin can be increased when combined with Carbamazepine.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Carbamazepine.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Carbamazepine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Carbamazepine.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Carbamazepine.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
DrospirenoneThe metabolism of Drospirenone can be increased when combined with Carbamazepine.
DuloxetineThe metabolism of Duloxetine can be increased when combined with Carbamazepine.
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Carbamazepine.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Carbamazepine.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Carbamazepine.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Carbamazepine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Carbamazepine.
ErythromycinThe metabolism of Carbamazepine can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Carbamazepine can be decreased when combined with Escitalopram.
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Eslicarbazepine acetate.
EstradiolThe metabolism of Estradiol can be increased when combined with Carbamazepine.
EstropipateThe metabolism of Estropipate can be increased when combined with Carbamazepine.
EthanolCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthoxzolamideThe serum concentration of Carbamazepine can be increased when it is combined with Ethoxzolamide.
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Carbamazepine.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Carbamazepine.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Carbamazepine.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Carbamazepine.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Carbamazepine.
EzogabineThe serum concentration of Ezogabine can be decreased when it is combined with Carbamazepine.
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Carbamazepine.
FelodipineThe metabolism of Felodipine can be increased when combined with Carbamazepine.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Carbamazepine.
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Carbamazepine.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Carbamazepine.
FluconazoleThe serum concentration of Carbamazepine can be increased when it is combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Carbamazepine.
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Carbamazepine.
FlunisolideThe metabolism of Flunisolide can be increased when combined with Carbamazepine.
FluoxetineThe metabolism of Carbamazepine can be decreased when combined with Fluoxetine.
FlutamideThe metabolism of Flutamide can be increased when combined with Carbamazepine.
FluvoxamineThe metabolism of Carbamazepine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Fosamprenavir can be increased when combined with Carbamazepine.
FosphenytoinThe serum concentration of Carbamazepine can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Carbamazepine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Carbamazepine.
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Carbamazepine.
HaloperidolThe metabolism of Haloperidol can be increased when combined with Carbamazepine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carbamazepine.
HydrocodoneCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Carbamazepine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Carbamazepine.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Carbamazepine.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Carbamazepine.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Carbamazepine.
IndinavirThe metabolism of Indinavir can be increased when combined with Carbamazepine.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be reduced when Irinotecan is used in combination with Carbamazepine resulting in a loss in efficacy.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Carbamazepine resulting in a loss in efficacy.
IsocarboxazidThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Isocarboxazid.
IsoflurophateThe metabolism of Isoflurophate can be increased when combined with Carbamazepine.
IsoniazidThe metabolism of Carbamazepine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Isradipine can be increased when combined with Carbamazepine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Carbamazepine.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Carbamazepine.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Carbamazepine.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Carbamazepine.
LacosamideCarbamazepine may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbamazepine.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Carbamazepine.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Carbamazepine.
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Carbamazepine.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Carbamazepine.
LidocaineThe metabolism of Lidocaine can be increased when combined with Carbamazepine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Carbamazepine.
LinezolidThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Linezolid.
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Carbamazepine.
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Carbamazepine.
LithiumThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Lithium.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Carbamazepine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carbamazepine.
LoxapineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Loxapine.
LuliconazoleThe serum concentration of Carbamazepine can be increased when it is combined with Luliconazole.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Carbamazepine.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Carbamazepine.
MACITENTANThe serum concentration of MACITENTAN can be decreased when it is combined with Carbamazepine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Carbamazepine.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Carbamazepine.
Medroxyprogesterone AcetateThe therapeutic efficacy of Medroxyprogesterone Acetate can be decreased when used in combination with Carbamazepine.
MefloquineThe therapeutic efficacy of Carbamazepine can be decreased when used in combination with Mefloquine.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Carbamazepine.
MethadoneThe metabolism of Methadone can be increased when combined with Carbamazepine.
MethazolamideThe serum concentration of Carbamazepine can be increased when it is combined with Methazolamide.
MethotrimeprazineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbamazepine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Carbamazepine.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Carbamazepine.
MetyrosineCarbamazepine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be increased when combined with Carbamazepine.
MianserinThe therapeutic efficacy of Carbamazepine can be decreased when used in combination with Mianserin.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Carbamazepine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
MirtazapineThe metabolism of Mirtazapine can be increased when combined with Carbamazepine.
MitotaneThe serum concentration of Carbamazepine can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Moclobemide.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Carbamazepine.
NefazodoneThe serum concentration of Carbamazepine can be increased when it is combined with Nefazodone.
NelfinavirThe metabolism of Nelfinavir can be increased when combined with Carbamazepine.
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Carbamazepine.
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Carbamazepine.
NicardipineThe metabolism of Nicardipine can be increased when combined with Carbamazepine.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Carbamazepine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Carbamazepine.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Carbamazepine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Carbamazepine.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Carbamazepine.
NorethindroneThe therapeutic efficacy of Norethindrone can be decreased when used in combination with Carbamazepine.
NorgestimateThe metabolism of Norgestimate can be increased when combined with Carbamazepine.
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Carbamazepine.
OlanzapineThe metabolism of Olanzapine can be increased when combined with Carbamazepine.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Carbamazepine.
OrlistatThe serum concentration of Carbamazepine can be decreased when it is combined with Orlistat.
OrphenadrineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxcarbazepineThe serum concentration of the active metabolites of Oxcarbazepine can be reduced when Oxcarbazepine is used in combination with Carbamazepine resulting in a loss in efficacy.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Carbamazepine.
PaliperidoneThe serum concentration of Paliperidone can be decreased when it is combined with Carbamazepine.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Carbamazepine.
PantoprazoleThe metabolism of Pantoprazole can be increased when combined with Carbamazepine.
ParaldehydeCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe metabolism of Carbamazepine can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Carbamazepine.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Carbamazepine.
PhenelzineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Phenelzine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Carbamazepine.
PimozideThe metabolism of Pimozide can be increased when combined with Carbamazepine.
PirfenidoneThe serum concentration of Pirfenidone can be decreased when it is combined with Carbamazepine.
PomalidomideThe metabolism of Pomalidomide can be increased when combined with Carbamazepine.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Carbamazepine.
PramipexoleCarbamazepine may increase the sedative activities of Pramipexole.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Carbamazepine.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Carbamazepine.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Carbamazepine.
ProcarbazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Procarbazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Carbamazepine.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Carbamazepine.
PropranololThe metabolism of Propranolol can be increased when combined with Carbamazepine.
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Carbamazepine.
QuetiapineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Quetiapine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Carbamazepine.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Carbamazepine.
RasagilineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Rasagiline.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Carbamazepine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Carbamazepine.
RiluzoleThe metabolism of Riluzole can be increased when combined with Carbamazepine.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Carbamazepine.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Carbamazepine.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Carbamazepine.
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Carbamazepine.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Carbamazepine.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Carbamazepine.
RopiniroleThe metabolism of Ropinirole can be increased when combined with Carbamazepine.
RotigotineCarbamazepine may increase the sedative activities of Rotigotine.
RufinamideThe serum concentration of Carbamazepine can be decreased when it is combined with Rufinamide.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Carbamazepine.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Carbamazepine.
SelegilineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Selegiline.
SertralineThe metabolism of Carbamazepine can be decreased when combined with Sertraline.
SildenafilThe metabolism of Sildenafil can be increased when combined with Carbamazepine.
SiltuximabThe serum concentration of Carbamazepine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Carbamazepine.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Carbamazepine.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Carbamazepine.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Carbamazepine.
St. John's WortThe serum concentration of Carbamazepine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Carbamazepine can be increased when it is combined with Stiripentol.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Carbamazepine.
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Carbamazepine.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Carbamazepine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Carbamazepine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Carbamazepine can be increased when it is combined with Telaprevir.
TelithromycinThe metabolism of Carbamazepine can be decreased when combined with Telithromycin.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Carbamazepine.
ThalidomideCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Carbamazepine.
ThiothixeneThe metabolism of Thiothixene can be increased when combined with Carbamazepine.
Thyroid extractThe serum concentration of Thyroid extract can be decreased when it is combined with Carbamazepine.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Carbamazepine resulting in a loss in efficacy.
TipranavirThe metabolism of Tipranavir can be increased when combined with Carbamazepine.
TocilizumabThe serum concentration of Carbamazepine can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Carbamazepine.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Carbamazepine.
TopiramateThe serum concentration of Topiramate can be decreased when it is combined with Carbamazepine.
TorasemideThe metabolism of Torasemide can be increased when combined with Carbamazepine.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Carbamazepine.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Carbamazepine.
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
TranylcypromineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tranylcypromine.
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Carbamazepine.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Carbamazepine.
TrifluoperazineThe metabolism of Trifluoperazine can be increased when combined with Carbamazepine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Carbamazepine.
Valproic AcidThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Valproic Acid.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Carbamazepine.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Carbamazepine.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Carbamazepine.
VerapamilThe serum concentration of Carbamazepine can be increased when it is combined with Verapamil.
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Carbamazepine.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Carbamazepine.
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Carbamazepine.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Carbamazepine.
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Carbamazepine.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Carbamazepine.
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Carbamazepine.
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Carbamazepine.
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Carbamazepine.
Food Interactions
  • Avoid alcohol.
  • Avoid taking grapefruit or grapefruit juice throughout treatment.
  • Grapefruit can significantly increase serum levels of this product.
  • Take with food, increases availability and reduces irritation.

Targets

1. Sodium channel protein type 5 subunit alpha

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sodium channel protein type 5 subunit alpha Q14524 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Yang YC, Huang CS, Kuo CC: Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal na+ channels. Anesthesiology. 2010 Jul;113(1):160-74. Pubmed
  4. Yang YC, Kuo CC: Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker. Mol Pharmacol. 2002 Nov;62(5):1228-37. Pubmed
  5. Lipkind GM, Fozzard HA: Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. Mol Pharmacol. 2010 Oct;78(4):631-8. Epub 2010 Jul 19. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. Pubmed
  2. Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia. 1995;36 Suppl 5:S8-13. Pubmed
  3. Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, Pons G: Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003 Nov;56(5):526-36. Pubmed
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inducer

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, Pons G: Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003 Nov;56(5):526-36. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2B6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2B6 P20813 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 3A5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

8. Cytochrome P450 3A7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

9. UDP-glucuronosyltransferase 2B7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 2B7 P16662 Details

References:

  1. Kim KA, Oh SO, Park PW, Park JY: Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur J Clin Pharmacol. 2005 Jun;61(4):275-80. Epub 2005 May 25. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. Pubmed
  2. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK: Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol. 2001 Apr;51(4):345-9. Pubmed
  3. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. Pubmed
  4. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. Pubmed
  5. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. Pubmed

2. RalA-binding protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
RalA-binding protein 1 Q15311 Details

References:

  1. Awasthi S, Hallene KL, Fazio V, Singhal SS, Cucullo L, Awasthi YC, Dini G, Janigro D: RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci. 2005 Sep 27;6:61. Pubmed

3. Canalicular multispecific organic anion transporter 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Canalicular multispecific organic anion transporter 1 Q92887 Details

References:

  1. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Hasler R, Faltraco F, Remmler C, von Spiczak S, Kroemer HK, Runge U, Boor R, Stephani U, Cascorbi I: Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics. 2009 May;19(5):353-62. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11